The safety and effects of the beta-blocker, nadolol, in mild asthma: An open-label pilot study

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 1, 2008, Pages 134-141

  Hanania, Nicola A ^a   Singh, Supria ^a   El Wali, Rami ^a   Flashner, Michael ^b   Franklin, Amie E ^b   Garner, William J ^b   Dickey, Burton F ^c   Parra, Sergio ^d   Ruoss, Stephen ^e   Shardonofsky, Felix ^f   O'Connor, Brian J ^g   Page, Clive ^h   Bond, Richard A ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Inverseon Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT DALLAS   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Airway hyperresponsiveness; Asthma; Beta blockers; Beta2 adrenoceptor agonist

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; METHACHOLINE; NADOLOL;

ADULT; ARTICLE; ASTHMA; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEMODYNAMICS; HUMAN; LUNG FUNCTION; MALE; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FUNCTION; SIDE EFFECT; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NADOLOL; PILOT PROJECTS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS;

EID: 38049005296     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2007.07.002     Document Type: Article

References (45)

1. Lipworth B.J. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?. Drug Saf 16 (1997) 295-308
2. Shore S.A., and Drazen J.M. Beta-agonists and asthma: too much of a good thing?. J Clin Invest 112 (2003) 495-497
3. Salpeter S.R., Buckley N.S., Ormiston T.M., and Salpeter E.E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144 (2006) 904-912
4. Abramson M.J., Walters J., and Walters E.H. Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med 2 (2003) 287-297
5. Cockcroft D.W., McParland C.P., Britto S.A., et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342 (1993) 833-837
6. Drazen J.M., Israel E., Boushey H.A., et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 335 (1996) 841-847
7. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
8. Weber K.T., Andrews V., and Janicki J.S. Cardiotonic agents in the management of chronic cardiac failure. Am Heart J 103 (1982) 639-649
9. Nicholas G., Oakley C., Pouleur H., Rouseeau M.F., et al. Xamoterol in severe heart failure. The xamoterol in Severe Heart Failure Study Group. Lancet 336 (1990) 1-6
10. Waagstein F., Hjalmarson A., Varnauskas E., and Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37 (1975) 1022-1036
11. Waagstein F., Hjalmarson A., Varnauskas E., and Wallentin I. Proceedings: chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 38 (1976) 537-538
12. Lechat P., Packer M., Chalon S., Cucherat M., Arab T., and Boissel J.P. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 98 (1998) 1184-1191
13. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators. Circulation 94 (1996) 2807-2816
14. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (1999) 78-86
15. Hall S.A., Cigarroa C.G., Marcoux L., et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25 (1995) 1154-1161
16. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
17. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283 (2000) 1295-1302
18. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334 (1996) 1349-1355
19. Callaerts-Vegh Z., Evans K.L., Dudekula N., Cuba D., Knoll B.J., Callaerts P.F., et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 101 (2004) 4948-4953
20. Abbott A. Beta-blocker goes on trial as asthma therapy. Nature 432 (2004) 7
21. Crapo R.O., Casaburi R., Coates A.L., et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 161 (2000) 309-329
22. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., and King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 14 (1999) 902-907
23. Lim S., Jatakanon A., John M., et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 159 (1999) 22-30
24. Kanniess F., Richter K., Bohme S., Jorres R.A., and Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 20 (2002) 853-858
25. Evans P.M., O'Connor B.J., Fuller R.W., Barnes P.J., and Chung K.F. Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 91 (1993) 643-650
26. Silkoff P.E., McClean P.A., Slutsky A.S., et al. Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. J Asthma 35 (1998) 473-479
27. Bond R.A. Can intellectualism stifle scientific discovery?. Nat Rev Drug Discov 1 (2002) 825-829
28. Bond R.A. Is paradoxical pharmacology a strategy worth pursuing?. Trends Pharmacol Sci 22 (2001) 273-276
29. Sears M.R., Taylor D.R., Print C.G., et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 336 (1990) 1391-1396
30. Taylor D.R., Sears M.R., Herbison G.P., et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 48 (1993) 134-138
31. Sears M.R. Adverse effects of beta-agonists. J Allergy Clin Immunol 110 (2002) S322-S328
32. Sears M.R., and Taylor D.R. Bronchodilator treatment in asthma. Increase in deaths during salmeterol treatment unexplained. Br Med J 306 (1993) 1610-1611
33. Salpeter S.R., Ormiston T.M., and Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 140 (2004) 802-813
34. Jackson C.M., and Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma. Drug Saf 27 (2004) 243-270
35. Mann M., Chowdhury B., Sullivan E., Nicklas R., Anthracite R., and Meyer R.J. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124 (2003) 70-74
36. Beasley R., Pearce N., Crane J., and Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality?. J Allergy Clin Immunol 104 (1999) S18-S30
37. Speizer F.E., Doll R., and Heaf P. Observations on recent increase in mortality from asthma. Br Med J 1 (1968) 335-339
38. Speizer F.E., Doll R., Heaf P., and Strang L.B. Investigation into use of drugs preceding death from asthma. Br Med J 1 (1968) 339-343
39. FDA, 2005. Serevent, Advair, Foradil withdrawals to be considered by advisory committee. Available from 〈www.thepinksheet.com/FDC/AdvisoryCommittee/Committees/Pulmonary-Allergy+Drugs/071305_betasafety/071305_BroncoP.htm〉.
40. McGraw D.W., Almoosa K.F., Paul R.J., Kobilka B.K., and Liggett S.B. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 112 (2003) 619-626
41. McGraw D.W., and Liggett S.B. Molecular mechanisms of beta2-adrenergic receptor function and regulation. Proc Am Thorac Soc 2 (2005) 292-296 discussion 311-292
42. Ind P.W., Dixon C.M., Fuller R.W., and Barnes P.J. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis 139 (1989) 1390-1394
43. Israel E., Drazen J.M., Liggett S.B., et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
44. Israel E., Chinchilli V.M., Ford J.G., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004) 1505-1512
45. Sont J.K., Willems L.N., Bel E.H., et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159 (1999) 1043-1051